Add like
Add dislike
Add to saved papers

Sleep symptoms signaling the menopausal transition.

STUDY OBJECTIVES: To describe changes in sleep quality and associated sleep symptoms as women begin menopausal transition compared to pre-menopausal controls.

METHODS: In a repeated measures design, we analyzed data collected every 2-6 months from a community-based sample of 223 women 40-50 (45.6±2.3) years old over a two-year period. Each 6-month visit included urinary follicle stimulating hormone (FSH) as a marker of ovarian function, Pittsburgh Sleep Quality Index (PSQI) and other questionnaires (Center for Epidemiological Studies-Depression Scale; Perceived Stress Scale). Menstrual cycle and vasomotor symptoms (Seattle Women's Health Symptom Checklist) were tracked every 2 months by phone. For women entering menopausal transition (n=68) we used data from the two consecutive visits prior to their FSH rise and the next two visits. Data from the last four consecutive visits were used for controls remaining pre-menopausal (n=155).

RESULTS: The transition group did not differ from controls on age, vasomotor symptoms (hot flashes/night sweats), stress or depression but did have a higher BMI. Measures were stable over time for controls. However, the transition group experienced an increase in PSQI scores (initial PSQI=5.7±3.2 and final PSQI 6.3±3.8, p=.030) and frequency of trouble sleeping because of feeling too hot (p=.016) that lagged the FSH rise by 6 months with no notable change in report of hot flashes/night sweats.

CONCLUSIONS: Trouble sleeping because of feeling too hot, distinct from awareness of vasomotor symptoms, was the only uniform contribution to higher PSQI scores after the initial FSH increase and may signal onset of the menopausal transition.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app